



European  
Commission

# Europe's Beating Cancer Plan



## Diagnosis and treatment

**Start date – end date**  
1/11/2022 – 31/10/2025

**Countries**  
Italy, Spain, Greece

**Overall budget**  
EUR 1 635 325

**EU contribution under  
EU4Health programme**  
EUR 981 195

## NEWROAD – Open Platform for European Networking and Repurposing of Oncological Assets and Drugs



**This project brings together complementary expertise to design new active molecules and also to repurpose existing drugs. Our ambition is to make an open platform for all European researchers.**

NEWROAD aims to develop an EU-wide capability for Systematic Drug Repurposing (SDR) in oncology. This platform will facilitate the identification of novel therapies for any disease of interest and ultimately any combination of diseases. The project will provide a comprehensive strategy to reduce therapy development costs and fast-track compounds that have passed toxicity tests.


The project's implementation phase includes:




**1. Developing the platform:** The foundation of the NEWROAD project is an advanced, user-friendly platform to enhance the discovery of novel therapies through systematic drug repurposing.



**2. Data collection and integration:** Data provided by various entities in the European Union, such as hospitals, clinics, and pharmaceutical companies, will be collected and integrated into the platform.



**3. Establishing a data sharing protocol:** A crucial aspect of this project is the facilitation of data sharing among different entities within the European Union. To this end, a comprehensive data sharing protocol will be established.



**4. Development and testing of novel therapies:** Once the platform is set up and data are integrated, the focus will shift towards the identification and development of novel therapies through drug repurposing. In silico testing will be performed on a selection of oncological targets, with Artificial Intelligence rationally guiding the selection process.

Project beneficiaries include healthcare providers who will have access to a powerful tool for developing novel therapies; patients, particularly those affected by rare and paediatric cancers, who stand to benefit from the development of effective new treatments; and the wider European Union, which will gain from the shared clinical data and collaborative nature of the platform.

### Expected results

The expected outcomes of the project include:



- the development of an EU-wide SDR platform for identifying novel therapies;
- reducing the time and cost associated with therapy development by repurposing approved drugs;
- improving the platform's predictive accuracy through shared clinical data;
- facilitating researcher collaboration and engagement;
- creating a new protocol of investigation, which performs in silico testing on a selection of oncological targets.

For more info

#### Contact details

Simona Concilio (University of Salerno, [sconcilio@unisa.it](mailto:sconcilio@unisa.it))

#### Project website

<https://new-road.eu/>

#### Funding Programme

EU4Health

#### Project Coordinator

UNISA - University of Salerno,  
<https://www.unisa.it/>



Europe's Beating Cancer Plan makes use of the whole range of Commission funding instruments with a total of €4 billion being earmarked for actions addressing cancer. €1.25 billion from the EU4Health programme is being used to support actions and initiatives outlined in the Cancer Plan.

© European Union, 2023

Reuse of this document is allowed, provided appropriate credit is given and any changes are indicated (Creative Commons Attribution 4.0 International license). For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders. All images © Gettyimages